10-K: Azenta, Inc. Reports Fiscal Year 2024 Results, Details Strategic Realignment and Goodwill Impairment

Azenta, Inc. reported a slight decrease in revenue for fiscal year 2024, alongside a significant net loss due to a goodwill impairment and increased operating expenses.

Summary

• Azenta, Inc.'s revenue decreased by 1% to $656.3 million in fiscal year 2024 compared to $665.1 million in fiscal year 2023.
• The company experienced a net loss of $164.2 million in fiscal year 2024, a significant drop from the $14.3 million net loss in fiscal year 2023.
• This loss was primarily driven by a $116 million non-cash impairment of goodwill and intangible assets, as well as increased restructuring costs.
• Gross margin increased slightly to 40.1% in fiscal year 2024 from 39.6% in fiscal year 2023.
• Operating expenses increased due to the goodwill impairment and restructuring costs, partially offset by decreased selling, general, and administrative expenses.
• The company realigned its organizational structure into three segments: Sample Management Solutions, Multiomics, and B Medical Systems, effective October 1, 2023.
• Sample Management Solutions revenue increased by 5%, while Multiomics revenue increased by 3%, and B Medical Systems revenue decreased by 27%.

Sentiment

Score: 3

Explanation: The document presents a challenging financial picture with a significant net loss and goodwill impairment. While there are some positive aspects like revenue growth in certain segments and improved gross margin, the overall tone is negative due to the substantial financial losses and identified material weakness in internal controls.

Positives

• Gross margin improved to 40.1% in fiscal year 2024, up from 39.6% in the previous year.
• Sample Management Solutions revenue increased by 5% year-over-year.
• Multiomics revenue increased by 3% year-over-year.
• The company implemented a transformation initiative to reduce complexity and streamline processes across the organization.

Negatives

• Azenta reported a net loss of $164.2 million in fiscal year 2024, a significant increase from the $14.3 million loss in fiscal year 2023.
• The company recorded a $116 million non-cash impairment of goodwill and intangible assets.
• B Medical Systems revenue decreased by 27% year-over-year.
• Operating expenses increased due to the goodwill impairment and restructuring costs.

Risks

• The company identified a material weakness in its internal control over financial reporting related to the review of the cash flow statement.
• The company is subject to risks associated with public health threats and epidemics.
• The company is exposed to risks associated with global climate change and related legal and regulatory developments.
• Unfavorable currency exchange rate fluctuations may impact the company's significant foreign currency holdings.
• The company's business could be negatively impacted by environmental, social and governance (ESG) matters.
• The company's operating results could fluctuate significantly, which could negatively impact its business.
• The company's business could be materially harmed if it fails to adequately integrate the operations of the businesses that it has acquired or may acquire.
• The company's business relies on certain critical information systems and a failure or breach of such a system could harm its business and results of operations.
• The company's goodwill and intangible assets may become impaired.
• International trade disputes could result in additional or increased tariffs, export controls or other trade restrictions that may have a material impact on the company's business.
• The company is subject to numerous governmental regulations.
• The company's actual or perceived failure to comply with data protection laws and regulations could lead to government enforcement actions, private litigation and/or adverse publicity and could negatively affect its business.
• The company's failure to protect its intellectual property could adversely affect its future operations.
• The company may be subject to claims of infringement of third-party intellectual property rights, or demands that it license third-party technology, which could result in significant expense and prevent it from using its technology.
• The company's business could be materially harmed if one or more key suppliers fail to continuously deliver key components of acceptable cost and quality.
• The company's business could be adversely affected by a decline in the availability of raw materials.
• The company's external service providers may fail to perform as expected or may suffer cybersecurity breaches.
• Customers generally do not make long term commitments to purchase the company's products and may cease purchasing at any time.
• The company may face claims for liability related to damages of customer materials attributed to the failure of its products or services, exposing it to significant financial or reputational harm.
• The company's stock price is volatile.
• The company's business and operations could be negatively affected by securities litigation or stockholder activism.
• Provisions in the company's charter documents and Delaware law may delay or prevent an acquisition of the company, which could decrease the value of shares.
• The company's by-laws designate the state courts in the State of Delaware as the sole and exclusive forum for certain types of actions and proceedings that may be initiated by its stockholders, which could discourage lawsuits against the company and its directors, officers and employees.

Future Outlook

The company expects to complete its transformation initiatives by the end of fiscal year 2026, which are designed to reduce costs and increase profitability. The company is also pursuing a sale of its B Medical Systems segment.

Management Comments

• The company is committed to making sure that every team member understands our core values of Customer Focus, Achievement, Accountability, Teamwork, Employee Value, and Integrity.
• The company's purpose is to enable life sciences organizations around the world to bring impactful and breakthrough therapies to market faster.

Industry Context

The company operates in the life sciences industry, which is experiencing growth due to advancements in biologics and personalized medicine. The company's focus on sample management and genomic solutions aligns with the increasing importance of biological samples in drug development and therapy pipelines.

Comparison to Industry Standards

• The company competes with Hamilton Company and Liconic AG in automation systems, and Laboratory Corporation of America Holdings and Thermo Fisher Scientific Inc. for storage, consumables and services.
• In the Multiomics segment, competitors include BGI Genomics Co., Ltd., Eurofins, Scientific S.E., GenScript Biotech Corporation, Integrated DNA Technologies, Inc., Novogene Co., Ltd., and Twist Bioscience Corporation.
• In the B Medical Systems segment, the company competes with Vestfrost Solutions and Haier Biomedical.

Management Changes

Corporate Governance

Legal Proceedings

• The company is subject to various legal proceedings, both asserted and unasserted, that arise in the ordinary course of business.
• The company is also subject to certain indemnification obligations pursuant to claims made under the definitive agreement it entered into with Edwards Vacuum LLC.

Stakeholder Impact

• Shareholders may be concerned about the significant net loss and goodwill impairment.
• Employees may be affected by the restructuring initiatives and changes in management.
• Customers may experience changes in product offerings and services due to the strategic realignment.
• Suppliers may be impacted by changes in the company's supply chain and manufacturing operations.
• Creditors may be concerned about the company's financial performance and ability to meet its obligations.

Next Steps

• The company will continue to implement its transformation initiatives to reduce costs and increase profitability.
• The company is pursuing a sale of its B Medical Systems segment.
• The company will continue to focus on developing processes and technologies that can streamline sample to data workflows.

Key Dates

Keywords

Life Sciences, Sample Management, Genomics, Cold Chain, Biotechnology, Pharmaceutical, Automated Storage, Multiomics, Financial Results, Goodwill Impairment